Department of Health Economics and Management Sciences, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran
Gheam Hospital, Women Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Resident of Obstetric and Gynecology
Tehran University of Medical Sciences, Tehran, Iran
- Khatibi M, Rasekh HR, Shahverdi Z, Jamshidi HR. Cost-eﬀectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran. Iran J Pharm Res. 2014;13(Suppl):225-34.
- Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1-30.
- Iarc Working Group on the Evaluation of Carcinogenic Risks to Humans . Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441.
- de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56. [DOI:10.1016/S1470-2045(10)70230-8]
- Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24 Suppl 3:S3/35-41. [DOI:10.1016/j.vaccine.2006.06.015] [PMID]
- WHO . Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43):465-91.